Your browser doesn't support javascript.
loading
Predictors of long-term survival after resection of adenocarcinoma arising from intraductal papillary mucinous neoplasm and derivation of a prognostic model: An international multicenter study (ADENO-IPMN study).
Lucocq, James; Joseph, Nejo; Hawkyard, Jake; Haugk, Beate; White, Steve; Lye, Jonathan; Parkinson, Daniel; Mownah, Omar; Menon, Krishna; Furukawa, Takaki; Hirose, Yuki; Sasahira, Naoki; Inoue, Yosuke; Mittal, Anubhav; Samra, Jas; Sheen, Amy; Feretis, Michael; Balakrishnan, Anita; Ceresa, Carlo; Davidson, Brian; Pande, Rupaly; Dasari, Bobby; Roberts, Keith; Tanno, Lulu; Karavias, Dimitrios; Helliwell, Jack; Young, Alistair; Marks, Kate; Nunes, Quentin; Urbonas, Tomas; Silva, Michael; Gordon-Weeks, Alex; Barrie, Jenifer; Gomez, Dhanny; van Laarhoven, Stijn; Nawara, Hossam; Doyle, Joseph; Bhogal, Ricky; Harrison, Ewen; Roalso, Marcus; Ciprani, Debora; Aroori, Somaiah; Ratnayake, Bathiya; Koea, Jonathan; Capurso, Gabriele; Stättner, Stefan; Bellotti, Ruben; Alsaoudi, Tareq; Bhardwaj, Neil; Rajesh, Srujan.
Afiliação
  • Lucocq J; Department of General surgery, NHS Lothian, UK.
  • Joseph N; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Hawkyard J; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Haugk B; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • White S; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Lye J; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Parkinson D; Hepatopancreatobiliary and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK.
  • Mownah O; Department of Hepatobiliary & Pancreatic Surgery, King's College Hospital, Denmark Hill, London, UK.
  • Menon K; Department of Hepatobiliary & Pancreatic Surgery, King's College Hospital, Denmark Hill, London, UK.
  • Furukawa T; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Hepato-Biliary-Pancreatic Medicine Department, Tokyo, Japan.
  • Hirose Y; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Hepato-Biliary-Pancreatic Medicine Department, Tokyo, Japan.
  • Sasahira N; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Hepato-Biliary-Pancreatic Medicine Department, Tokyo, Japan.
  • Inoue Y; Cancer Institute Hospital of Japanese Foundation for Cancer Research, Hepato-Biliary-Pancreatic Medicine Department, Tokyo, Japan.
  • Mittal A; Royal North Shore Hospital, Sydney, NSW, Australia.
  • Samra J; Royal North Shore Hospital, Sydney, NSW, Australia.
  • Sheen A; New South Wales Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, NSW, Australia.
  • Feretis M; Cambridge Hepatobiliary and Pancreatic Surgery Unit, Addenbrooke's Hospital, Cambridge, UK.
  • Balakrishnan A; Cambridge Hepatobiliary and Pancreatic Surgery Unit, Addenbrooke's Hospital, Cambridge, UK.
  • Ceresa C; Hepatobiliary and Pancreatic Surgery Unit, The Royal Free Hospital, London, UK.
  • Davidson B; Hepatobiliary and Pancreatic Surgery Unit, The Royal Free Hospital, London, UK.
  • Pande R; Hepatobiliary and Pancreatic Surgery Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK.
  • Dasari B; Hepatobiliary and Pancreatic Surgery Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK.
  • Roberts K; Hepatobiliary and Pancreatic Surgery Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, UK.
  • Tanno L; Hepatobiliary and Pancreatic Surgery Unit, University Hospital Southampton, Southampton, UK.
  • Karavias D; Hepatobiliary and Pancreatic Surgery Unit, University Hospital Southampton, Southampton, UK.
  • Helliwell J; Hepatobiliary and Pancreatic Surgery Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Young A; Hepatobiliary and Pancreatic Surgery Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Marks K; Hepatobiliary and Pancreatic Surgery Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Nunes Q; Department of Hepatopancreatobiliary Surgery, East Lancashire Teaching Hospitals NHS Trust, UK.
  • Urbonas T; Oxford Hepato-Pancreato-Biliary (HPB) Surgical Unit, Oxford University Hospitals NHS Foundation Trust, UK.
  • Silva M; Oxford Hepato-Pancreato-Biliary (HPB) Surgical Unit, Oxford University Hospitals NHS Foundation Trust, UK.
  • Gordon-Weeks A; Oxford Hepato-Pancreato-Biliary (HPB) Surgical Unit, Oxford University Hospitals NHS Foundation Trust, UK.
  • Barrie J; Nottingham Hepato-Pancreatico-Biliary (HPB) Service, Nottingham University Hospitals NHS Foundation Trust, UK.
  • Gomez D; Nottingham Hepato-Pancreatico-Biliary (HPB) Service, Nottingham University Hospitals NHS Foundation Trust, UK.
  • van Laarhoven S; Department of Hepatobiliary and Pancreatic Surgery, University Hospitals Bristol & Weston NHS Foundation trust, UK.
  • Nawara H; Department of Hepatobiliary and Pancreatic Surgery, University Hospitals Bristol & Weston NHS Foundation trust, UK.
  • Doyle J; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Bhogal R; Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Harrison E; Department of Clinical Surgery, University of Edinburgh, UK.
  • Roalso M; Department of Gastrointestinal Surgery, Stavanger University Hospital, Norway.
  • Ciprani D; Hepatopancreatobiliary Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Aroori S; Hepatopancreatobiliary Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK.
  • Ratnayake B; Hepato-Pancreatico-Biliary/Upper Gastrointestinal Unit, North Shore Hospital, Auckland, NZ.
  • Koea J; Hepato-Pancreatico-Biliary/Upper Gastrointestinal Unit, North Shore Hospital, Auckland, NZ.
  • Capurso G; Digestive and Disease Unit, S. Andrea Hospital, Rome, Italy; Pancreas Center, San Raffaele Scientific Institute IRCCS, Vita Salute San Raffaele University, Milan, Italy.
  • Stättner S; Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Austria.
  • Bellotti R; Leicester Hepatopancreatobiliary Unit, University Hospitals of Leicester NHS Trust, UK.
  • Alsaoudi T; Leicester Hepatopancreatobiliary Unit, University Hospitals of Leicester NHS Trust, UK.
  • Bhardwaj N; Leicester Hepatopancreatobiliary Unit, University Hospitals of Leicester NHS Trust, UK.
  • Rajesh S; Leicester Hepatopancreatobiliary Unit, University Hospitals of Leicester NHS Trust, UK.
Surgery ; 2024 Jun 24.
Article em En | MEDLINE | ID: mdl-38918108
ABSTRACT

BACKGROUND:

Predictors of long-term survival after resection of adenocarcinoma arising from intraductal papillary mucinous neoplasms are unknown. This study determines predictors of long-term (>5 years) disease-free survival and recurrence in adenocarcinoma arising from intraductal papillary mucinous neoplasms and derives a prognostic model for disease-free survival.

METHODS:

Consecutive patients who underwent pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasms in 18 academic pancreatic centers in Europe and Asia between 2010 to 2017 with at least 5-year follow-up were identified. Factors associated with disease-free survival were determined using Cox proportional hazards model. Internal validation was performed, and discrimination and calibration indices were assessed.

RESULTS:

In the study, 288 patients (median age, 70 years; 52% male) were identified; 140 (48%) patients developed recurrence after a median follow-up of 98 months (interquartile range, 78.4-123), 57 patients (19.8%) developed locoregional recurrence, and 109 patients (37.8%) systemic recurrence. At 5 years after resection, the overall and disease-free survival was 46.5% (134/288) and 35.0% (101/288), respectively. On Cox proportional hazards model analysis, multivisceral resection (hazard ratio, 2.20; 95% confidence interval, 1.06-4.60), pancreatic tail location (hazard ratio, 2.34; 95% confidence interval, 1.22-4.50), poor tumor differentiation (hazard ratio, 2.48; 95% confidence interval, 1.10-5.30), lymphovascular invasion (hazard ratio, 1.74; 95% confidence interval, 1.06-2.88), and perineural invasion (hazard ratio, 1.83; 95% confidence interval, 1.09-3.10) were negatively associated with long-term disease-free survival. The final predictive model incorporated 8 predictors and demonstrated good predictive ability for disease-free survival (C-index, 0.74; calibration, slope 1.00).

CONCLUSION:

A third of patients achieve long-term disease-free survival (>5 years) after pancreatic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasms. The predictive model developed in the current study can be used to estimate the probability of long-term disease-free survival.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article